治疗药物-话题@MedSci

#治疗药物#

300篇内容 | 2603人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1921847, encodeId=f762192184e1f, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=J Clin Oncol：选择乳腺癌内分泌治疗药物，要注意什么？, objectType=article, longId=217715, objectId=298721e71540, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=298721e71540, replyNumber=0, likeNumber=72, createdTime=2022-05-19, rootId=0, userName=周虎, userId=c9d3459, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=298721e71540, moduleTitle=J Clin Oncol：选择乳腺癌内分泌治疗药物，要注意什么？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=298721e71540)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1921855, encodeId=96d11921855f2, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=2021年11月7日简报：全球新冠重症人数降至一年来很低值；国内10.72亿人完成新冠疫苗全程接种，其中3-11岁儿童接种新冠疫苗超353万剂次；新冠口服治疗药物可能会引入国内, objectType=article, longId=219924, objectId=c6972199240c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c6972199240c, replyNumber=0, likeNumber=74, createdTime=2022-01-29, rootId=0, userName=周虎, userId=c9d3459, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c6972199240c, moduleTitle=2021年11月7日简报：全球新冠重症人数降至一年来很低值；国内10.72亿人完成新冠疫苗全程接种，其中3-11岁儿童接种新冠疫苗超353万剂次；新冠口服治疗药物可能会引入国内, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c6972199240c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1921837, encodeId=a3de192183ead, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=Celltrion的新冠肺炎单克隆抗体治疗药物瑞丹维单抗对德尔塔变异株显示出强效中和活性, objectType=article, longId=214479, objectId=3d532144e904, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d532144e904, replyNumber=0, likeNumber=51, createdTime=2021-09-30, rootId=0, userName=周虎, userId=c9d3459, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d532144e904, moduleTitle=Celltrion的新冠肺炎单克隆抗体治疗药物瑞丹维单抗对德尔塔变异株显示出强效中和活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d532144e904)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1921828, encodeId=cb341921828c0, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=PD-1免疫治疗药物拓益®尿路上皮癌适应症在中国获批, objectType=article, longId=209983, objectId=86f62099835f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=86f62099835f, replyNumber=0, likeNumber=90, createdTime=2021-09-15, rootId=0, userName=周虎, userId=c9d3459, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=86f62099835f, moduleTitle=PD-1免疫治疗药物拓益®尿路上皮癌适应症在中国获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=86f62099835f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1921860, encodeId=527f192186059, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=LEO Pharma宣布FDA核准Adbry™ (tralokinumab)作为特异性靶向作用于中度至重度特应性皮炎成人IL-13的治疗药物, objectType=article, longId=293187, objectId=acae29318e52, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=acae29318e52, replyNumber=0, likeNumber=77, createdTime=2022-04-03, rootId=0, userName=周虎, userId=c9d3459, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=acae29318e52, moduleTitle=LEO Pharma宣布FDA核准Adbry™ (tralokinumab)作为特异性靶向作用于中度至重度特应性皮炎成人IL-13的治疗药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=acae29318e52)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1921843, encodeId=aea3192184390, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=Cell：新生儿胆道闭锁发病机制被揭示，利妥昔单抗可能成为潜在治疗药物, objectType=article, longId=215750, objectId=dfaa215e5085, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dfaa215e5085, replyNumber=0, likeNumber=65, createdTime=2022-01-15, rootId=0, userName=周虎, userId=c9d3459, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dfaa215e5085, moduleTitle=Cell：新生儿胆道闭锁发病机制被揭示，利妥昔单抗可能成为潜在治疗药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dfaa215e5085)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1921826, encodeId=e5fa19218261f, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=武田针对急性遗传性血管性水肿发作的治疗药物飞泽优®获批，保障中国HAE患者生命安全, objectType=article, longId=209352, objectId=229a20935293, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=229a20935293, replyNumber=0, likeNumber=89, createdTime=2021-11-16, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=229a20935293, moduleTitle=武田针对急性遗传性血管性水肿发作的治疗药物飞泽优®获批，保障中国HAE患者生命安全, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=229a20935293)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1921862, encodeId=03631921862a5, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=中国首张单片双药HIV治疗药物多伟托®医保处方落地，引领“简化治疗”新趋势！, objectType=article, longId=293418, objectId=0675293418b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0675293418b2, replyNumber=0, likeNumber=105, createdTime=2022-12-13, rootId=0, userName=周虎, userId=c9d3459, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0675293418b2, moduleTitle=中国首张单片双药HIV治疗药物多伟托®医保处方落地，引领“简化治疗”新趋势！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0675293418b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1921853, encodeId=7d671921853dc, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=辉凌将在ACG 2021上展示基于微生物群的在研活体生物治疗药物RBX2660用于治疗艰难梭菌反复感染和IBD患者的获奖真实临床转归分析, objectType=article, longId=218930, objectId=f8aa218930cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8aa218930cc, replyNumber=0, likeNumber=53, createdTime=2022-09-30, rootId=0, userName=周虎, userId=c9d3459, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8aa218930cc, moduleTitle=辉凌将在ACG 2021上展示基于微生物群的在研活体生物治疗药物RBX2660用于治疗艰难梭菌反复感染和IBD患者的获奖真实临床转归分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8aa218930cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1921858, encodeId=1edc192185876, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=辉瑞疫苗对奥密克戎的中和活性降低40多倍，我国新冠病毒中和抗体联合治疗药物获批丨新冠研究一周进展, objectType=article, longId=291882, objectId=027e29188207, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=027e29188207, replyNumber=0, likeNumber=99, createdTime=2022-02-16, rootId=0, userName=周虎, userId=c9d3459, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=027e29188207, moduleTitle=辉瑞疫苗对奥密克戎的中和活性降低40多倍，我国新冠病毒中和抗体联合治疗药物获批丨新冠研究一周进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=027e29188207)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1921846, encodeId=bc51192184667, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=武田的EXKIVITY™ (mobocertinib)成为美国FDA首次核准的专为EGFR外显子20插入+ NSCLC患者设计的口服治疗药物, objectType=article, longId=217428, objectId=aa6621e428d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa6621e428d6, replyNumber=0, likeNumber=77, createdTime=2022-08-06, rootId=0, userName=周虎, userId=c9d3459, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa6621e428d6, moduleTitle=武田的EXKIVITY™ (mobocertinib)成为美国FDA首次核准的专为EGFR外显子20插入+ NSCLC患者设计的口服治疗药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aa6621e428d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1921849, encodeId=d1de1921849cf, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=2021年10月1日简报：新冠疫情致欧美多国人口预期寿命缩短；新冠疫情将进入新常态，年底可能会上市多种新冠病毒口服治疗药物；仅15个非洲国家完成了10%的新冠疫苗接种阶段目标, objectType=article, longId=218016, objectId=57d62180164a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=57d62180164a, replyNumber=0, likeNumber=66, createdTime=2021-11-13, rootId=0, userName=周虎, userId=c9d3459, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=57d62180164a, moduleTitle=2021年10月1日简报：新冠疫情致欧美多国人口预期寿命缩短；新冠疫情将进入新常态，年底可能会上市多种新冠病毒口服治疗药物；仅15个非洲国家完成了10%的新冠疫苗接种阶段目标, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=57d62180164a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1921850, encodeId=edd3192185082, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=ERJ：肺动脉高压治疗药物会引起某些患者的动脉氧合血红蛋白饱和度 (SaO) 降低？, objectType=article, longId=218398, objectId=04ab21839831, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04ab21839831, replyNumber=0, likeNumber=81, createdTime=2022-04-17, rootId=0, userName=周虎, userId=c9d3459, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04ab21839831, moduleTitle=ERJ：肺动脉高压治疗药物会引起某些患者的动脉氧合血红蛋白饱和度 (SaO) 降低？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=04ab21839831)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1921832, encodeId=24dd19218327b, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=Advanced Science：以子之矛、攻子之盾，南大董磊团队利用凋亡小体突破血脑屏障，递送治疗药物, objectType=article, longId=211149, objectId=005c211149c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=005c211149c7, replyNumber=0, likeNumber=86, createdTime=2021-05-20, rootId=0, userName=周虎, userId=c9d3459, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=005c211149c7, moduleTitle=Advanced Science：以子之矛、攻子之盾，南大董磊团队利用凋亡小体突破血脑屏障，递送治疗药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=005c211149c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1921848, encodeId=8b5a1921848b7, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=辉凌将在IDWeek 2021上呈报基于微生物组的在研活体生物治疗药物RBX2660的获奖里程碑式研究, objectType=article, longId=217802, objectId=61bb21e8022f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61bb21e8022f, replyNumber=0, likeNumber=68, createdTime=2022-04-02, rootId=0, userName=周虎, userId=c9d3459, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61bb21e8022f, moduleTitle=辉凌将在IDWeek 2021上呈报基于微生物组的在研活体生物治疗药物RBX2660的获奖里程碑式研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=61bb21e8022f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1921838, encodeId=cf1419218381d, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=拜耳全新症状性慢性心衰治疗药物维立西呱在欧盟获批, objectType=article, longId=209867, objectId=cdf020986e23, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cdf020986e23, replyNumber=0, likeNumber=45, createdTime=2021-12-23, rootId=0, userName=周虎, userId=c9d3459, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cdf020986e23, moduleTitle=拜耳全新症状性慢性心衰治疗药物维立西呱在欧盟获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cdf020986e23)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1921820, encodeId=caee1921820e7, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=葛兰素史克中枢神经系统治疗药物利必通获批双相情感障碍新适应症, objectType=article, longId=208131, objectId=91b320813104, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=91b320813104, replyNumber=0, likeNumber=63, createdTime=2021-11-29, rootId=0, userName=周虎, userId=c9d3459, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=91b320813104, moduleTitle=葛兰素史克中枢神经系统治疗药物利必通获批双相情感障碍新适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=91b320813104)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1921840, encodeId=ef5c19218409b, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=Nat Cancer：新辅助治疗药物卡博替尼和纳武单抗治疗局部晚期肝细胞癌, objectType=article, longId=215171, objectId=df392151e1d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df392151e1d8, replyNumber=0, likeNumber=51, createdTime=2021-09-14, rootId=0, userName=周虎, userId=c9d3459, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df392151e1d8, moduleTitle=Nat Cancer：新辅助治疗药物卡博替尼和纳武单抗治疗局部晚期肝细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df392151e1d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1921814, encodeId=12cd1921814e5, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=EMA授予泡泡男孩病两项基因治疗药物的孤儿药资格, objectType=article, longId=204054, objectId=9c21204054f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c21204054f5, replyNumber=0, likeNumber=61, createdTime=2021-10-08, rootId=0, userName=周虎, userId=c9d3459, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c21204054f5, moduleTitle=EMA授予泡泡男孩病两项基因治疗药物的孤儿药资格, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c21204054f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1921851, encodeId=f67a192185142, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=武田与JCR Pharmaceuticals合作，将亨特综合征下一代治疗药物商业化, objectType=article, longId=218421, objectId=20732184217a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=20732184217a, replyNumber=0, likeNumber=69, createdTime=2021-11-13, rootId=0, userName=周虎, userId=c9d3459, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=20732184217a, moduleTitle=武田与JCR Pharmaceuticals合作，将亨特综合征下一代治疗药物商业化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=20732184217a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

治疗药物

2020-05-29

周虎 (审核中...)

前往app查看评论内容

#治疗药物#

J Clin Oncol：选择乳腺癌内分泌治疗药物，要注意什么？

2022-05-19

周虎 (审核中...)

前往app查看评论内容

#治疗药物#

2021年11月7日简报：全球新冠重症人数降至一年来很低值；国内10.72亿人完成新冠疫苗全程接种，其中3-11岁儿童接种新冠疫苗超353万剂次；新冠口服治疗药物可能会引入国内

2022-01-29

周虎 (审核中...)

前往app查看评论内容

#治疗药物#

Celltrion的新冠肺炎单克隆抗体治疗药物瑞丹维单抗对德尔塔变异株显示出强效中和活性

2021-09-30

周虎 (审核中...)

前往app查看评论内容

#治疗药物#

PD-1免疫治疗药物拓益®尿路上皮癌适应症在中国获批

2021-09-15

周虎 (审核中...)

前往app查看评论内容

#治疗药物#

LEO Pharma宣布FDA核准Adbry™ (tralokinumab)作为特异性靶向作用于中度至重度特应性皮炎成人IL-13的治疗药物

2022-04-03

周虎 (审核中...)

前往app查看评论内容

#治疗药物#

Cell：新生儿胆道闭锁发病机制被揭示，利妥昔单抗可能成为潜在治疗药物

2022-01-15

一叶知秋 (审核中...)

前往app查看评论内容

#治疗药物#

武田针对急性遗传性血管性水肿发作的治疗药物飞泽优®获批，保障中国HAE患者生命安全

2021-11-16

周虎 (审核中...)

前往app查看评论内容

#治疗药物#

中国首张单片双药HIV治疗药物多伟托®医保处方落地，引领“简化治疗”新趋势！

2022-12-13

周虎 (审核中...)

前往app查看评论内容

#治疗药物#

辉凌将在ACG 2021上展示基于微生物群的在研活体生物治疗药物RBX2660用于治疗艰难梭菌反复感染和IBD患者的获奖真实临床转归分析

2022-09-30

周虎 (审核中...)

前往app查看评论内容

#治疗药物#

辉瑞疫苗对奥密克戎的中和活性降低40多倍，我国新冠病毒中和抗体联合治疗药物获批丨新冠研究一周进展

2022-02-16

周虎 (审核中...)

前往app查看评论内容

#治疗药物#

武田的EXKIVITY™ (mobocertinib)成为美国FDA首次核准的专为EGFR外显子20插入+ NSCLC患者设计的口服治疗药物

2022-08-06

周虎 (审核中...)

前往app查看评论内容

#治疗药物#

2021年10月1日简报：新冠疫情致欧美多国人口预期寿命缩短；新冠疫情将进入新常态，年底可能会上市多种新冠病毒口服治疗药物；仅15个非洲国家完成了10%的新冠疫苗接种阶段目标

2021-11-13

周虎 (审核中...)

前往app查看评论内容

#治疗药物#

ERJ：肺动脉高压治疗药物会引起某些患者的动脉氧合血红蛋白饱和度 (SaO) 降低？

2022-04-17

周虎 (审核中...)

前往app查看评论内容

#治疗药物#

Advanced Science：以子之矛、攻子之盾，南大董磊团队利用凋亡小体突破血脑屏障，递送治疗药物

2021-05-20

周虎 (审核中...)

前往app查看评论内容

#治疗药物#

辉凌将在IDWeek 2021上呈报基于微生物组的在研活体生物治疗药物RBX2660的获奖里程碑式研究

2022-04-02

周虎 (审核中...)

前往app查看评论内容

#治疗药物#

拜耳全新症状性慢性心衰治疗药物维立西呱在欧盟获批

2021-12-23

周虎 (审核中...)

前往app查看评论内容

#治疗药物#

葛兰素史克中枢神经系统治疗药物利必通获批双相情感障碍新适应症

2021-11-29

周虎 (审核中...)

前往app查看评论内容

#治疗药物#

Nat Cancer：新辅助治疗药物卡博替尼和纳武单抗治疗局部晚期肝细胞癌

2021-09-14

周虎 (审核中...)

前往app查看评论内容

#治疗药物#

EMA授予泡泡男孩病两项基因治疗药物的孤儿药资格

2021-10-08

周虎 (审核中...)

前往app查看评论内容

#治疗药物#

武田与JCR Pharmaceuticals合作，将亨特综合征下一代治疗药物商业化

2021-11-13

科室
- - 订阅+
  - 更多科室
工具
服务